Published in
American Association for Cancer Research, Clinical Cancer Research, 16(27), p. 4459-4461, 2021
DOI: 10.1158/1078-0432.ccr-21-1353
Links
Tools
Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
Journal article published in 2021 by
Honey K. Oberoi,
Elena Garralda 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile. See related article by Johnson et al., p. 4521